BILL ANALYSIS

S1929

BULLISH

SEPSIS Act

S1929 (SEPSIS Act) carries an AI-assessed market impact score of 4/10 with a bullish outlook for investors. This legislation directly affects $BDX, Thermo Fisher Scientific ($TMO), $LH and $DGX and 2 other tickers. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

4/10

Impact Score

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

The SEPSIS Act (S.1929) establishes new federal programs for sepsis research, diagnosis, and treatment, creating future revenue opportunities for healthcare companies.

The bill is in early stages (referred to committee) but has strong legislative momentum due to Senate Majority Leader Schumer's sponsorship and a House companion bill (HR7116).

The bill authorizes programs that will require subsequent appropriations, meaning actual funding is not yet secured but the policy framework is being laid.

Companies involved in medical diagnostics, device manufacturing, and clinical research are structural beneficiaries.

How S1929 Affects the Market

The SEPSIS Act, if enacted and funded, would create new demand for medical diagnostics, devices, and research services related to sepsis. This presents a long-term bullish catalyst for companies like Becton, Dickinson and Company ($BDX), Thermo Fisher Scientific Inc. ($TMO), Labcorp Holdings Inc. ($LH), Quest Diagnostics Incorporated ($DGX), Abbott Laboratories ($ABT), and GE HealthCare Technologies Inc. ($GEHC). While these companies have shown mixed performance recently, with most experiencing 30-day declines, the legislative progress of this bill could provide future tailwinds. For example, $LH is currently at $274.46 and $DGX at $198.96, both showing positive 7-day changes, suggesting some short-term upward movement in the diagnostics sector, though not directly attributable to this bill at its current stage.

Bill Details

Metric	Value
Bill Number	S1929
Impact Score	4/10Certainty: Introduced/Referred (+1.0 companion bill) · Financial Magnitude: No explicit funding identified · Strategic Weight: AI qualitative assessment: 6/10 · Market Penetration: 6 companies — very broad impact
Market Sentiment	bullish
Event Date	June 3, 2025
Affected Sectors	Healthcare
Affected Stocks	$BDX, Thermo Fisher Scientific ($TMO), $LH, $DGX, Abbott Laboratories ($ABT), GE HealthCare ($GEHC)
Source	View on Congress.gov →

Summary

The SEPSIS Act (S.1929) establishes new federal programs for sepsis research, diagnosis, and treatment, creating new revenue streams for medical diagnostics, device manufacturers, and clinical research companies. Senate Majority Leader Schumer's sponsorship and a House companion bill (HR7116) indicate strong legislative momentum for this early-stage bill. The bill does not specify a funding amount, but authorizes programs that would require future appropriations.

Full AI Market Analysis

The SEPSIS Act (S.1929), introduced on June 3, 2025, and referred to the Committee on Health, Education, Labor, and Pensions, aims to establish programs to reduce rates of sepsis. This bill is in its early legislative stages, having been read twice and referred to committee. A companion bill, HR7116, has been introduced in the House, increasing the probability of eventual passage. The bill itself does not appropriate funds but authorizes the creation of new programs within the Centers for Disease Control and Prevention (CDC) to lead education campaigns, improve data collection, and support research related to sepsis. These authorized programs would require subsequent appropriations bills to allocate actual funding. The bill explicitly states findings that highlight the need for increased federal investment in sepsis research and support for the infectious disease workforce. This creates a clear path for future federal spending in these areas. Structural beneficiaries of this legislation, should it pass and be funded, include companies involved in medical diagnostics, device manufacturing, and clinical research. Specifically, companies like Becton, Dickinson and Company ($BDX), Thermo Fisher Scientific Inc. ($TMO), Labcorp Holdings Inc. ($LH), Quest Diagnostics Incorporated ($DGX), Abbott Laboratories ($ABT), and GE HealthCare Technologies Inc. ($GEHC) are well-positioned. These companies provide diagnostic tools, medical devices, and laboratory services that would be essential for new federal programs focused on sepsis detection, treatment, and research. Recent market data shows mixed performance for these companies. Over the last 7 days, $BDX is up +0.41%, $TMO is up +1.7%, $LH is up +4.12%, $DGX is up +0.91%, $ABT is up +0.41%, and $GEHC is up +2.37%. However, over the last 30 days, most have seen declines: $BDX is down -8.6%, $TMO is down -5.91%, $LH is down -0.53%, $DGX is down -2.46%, $ABT is down -7.87%, and $GEHC is down -8.7%. This indicates that the market has not yet priced in the potential impact of this early-stage legislation, and recent movements are likely driven by broader market or company-specific factors unrelated to the SEPSIS Act. The next legislative steps involve committee consideration and potential mark-up, followed by a vote in the Senate, and then the House.